Skip to main content
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases 8/2009

01.08.2009 | Brief Report

Nationwide surveillance of antimicrobial resistance among Haemophilus influenzae and Streptococcus pneumoniae in intensive care units in Taiwan

verfasst von: S.-S. Jean, P.-R. Hsueh, W.-S. Lee, H.-T. Chang, M.-Y. Chou, I.-S. Chen, J.-H. Wang, C.-F. Lin, J.-M. Shyr, W.-C. Ko, J.-J. Wu, Y.-C. Liu, W.-K. Huang, L.-J. Teng, C.-Y. Liu

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 8/2009

Einloggen, um Zugang zu erhalten

Abstract

A nationwide susceptibility surveillance of Streptococcus pneumoniae and Haemophilus influenzae isolates collected from patients treated at the intensive care units (ICUs) of ten Taiwanese major teaching hospitals was conducted from September 2005 through November 2005. High rates of resistance (intermediate/resistant) of S. pneumoniae to penicillin (85% resistance), ceftriaxone (46%/20%), and cefepime (43%/15%) by meningitis criteria, and in contrast, non-susceptibilities (intermediate/resistant) to penicillin (0%/0%), ceftriaxone (20%/0%) and cefepime (15%/0%) by non-meningitis criteria were noted (p values < 0.05) by the Clinical and Laboratory Standards Institute 2008. Resistant rate of S. pneumoniae to azithromycin was also high (63%). S. pneumoniae isolates were significantly more susceptible to ertapenem (87%) than to imipenem (39%) and meropenem (44%) (p values < 0.05). Rates of non-susceptibilities of H. influenzae isolates to ampicillin and cefaclor were high (55% and 45%, respectively). No β-lactamase-negative ampicillin-resistant (BLNAR) H. influenzae isolates were found. Imipenem has a notably higher MIC90 value (8 μg/ml) for H. influenzae than that of the other two carbapenems. Tigecycline showed good in vitro activities against these two respiratory pathogens. High rates of resistance among isolates of S. pneumoniae and H. influenzae continue to exist in the ICUs of Taiwan.
Literatur
1.
Zurück zum Zitat Lau YJ, Hsueh PR, Liu YC, Shyr JM, Huang WK, Teng LJ, Liu CY, Luh KT (2006) Comparison of in vitro activities of tigecycline with other antimicrobial agents against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in Taiwan. Microb Drug Resist 12:130–135. doi:10.1089/mdr.2006.12.130 PubMedCrossRef Lau YJ, Hsueh PR, Liu YC, Shyr JM, Huang WK, Teng LJ, Liu CY, Luh KT (2006) Comparison of in vitro activities of tigecycline with other antimicrobial agents against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in Taiwan. Microb Drug Resist 12:130–135. doi:10.​1089/​mdr.​2006.​12.​130 PubMedCrossRef
2.
Zurück zum Zitat Hsueh PR, Liu YC, Yang D, Yan JJ, Wu TL, Huang WK, Wu JJ, Ko WC, Leu HS, Yu CR, Luh KT (2001) Multicenter surveillance of antimicrobial resistance of major bacterial pathogens in intensive care units in 2000 in Taiwan. Microb Drug Resist 7:373–382. doi:10.1089/10766290152773383 PubMedCrossRef Hsueh PR, Liu YC, Yang D, Yan JJ, Wu TL, Huang WK, Wu JJ, Ko WC, Leu HS, Yu CR, Luh KT (2001) Multicenter surveillance of antimicrobial resistance of major bacterial pathogens in intensive care units in 2000 in Taiwan. Microb Drug Resist 7:373–382. doi:10.​1089/​1076629015277338​3 PubMedCrossRef
3.
Zurück zum Zitat CLSI (2005) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 6th edn. Approved standard M7-A6. Clinical and Laboratory Standards Institute, Wayne, PA, USA CLSI (2005) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 6th edn. Approved standard M7-A6. Clinical and Laboratory Standards Institute, Wayne, PA, USA
4.
Zurück zum Zitat CLSI (2008) Performance standards for antimicrobial susceptibility testing, 15th informational supplement. Supplemental tables M100-S18. Clinical and Laboratory Standards Institute, Wayne, PA, USA CLSI (2008) Performance standards for antimicrobial susceptibility testing, 15th informational supplement. Supplemental tables M100-S18. Clinical and Laboratory Standards Institute, Wayne, PA, USA
5.
Zurück zum Zitat Whitney CG, Farley MM, Hadler J, Harrison LH, Lexau C, Reingold A, Lefkowitz L, Cieslak PR, Cetron M, Zell ER, Jorgensen JH, Schuchat A, Active Bacterial Core Surveillance Program of the Emerging Infections Program Network (2000) Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 343:1917–1924. doi:10.1056/NEJM200012283432603 PubMedCrossRef Whitney CG, Farley MM, Hadler J, Harrison LH, Lexau C, Reingold A, Lefkowitz L, Cieslak PR, Cetron M, Zell ER, Jorgensen JH, Schuchat A, Active Bacterial Core Surveillance Program of the Emerging Infections Program Network (2000) Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 343:1917–1924. doi:10.​1056/​NEJM200012283432​603 PubMedCrossRef
6.
Zurück zum Zitat Hilliard NJ, Johnson CN, Armstrong SH, Quarles S, Waites KB (2002) In vitro activity of ertapenem (MK-0826) against multi-drug resistant Streptococcus pneumoniae compared with 13 other antimicrobials. Int J Antimicrob Agents 20:136–140. doi:10.1016/S0924-8579(02)00129-2 PubMedCrossRef Hilliard NJ, Johnson CN, Armstrong SH, Quarles S, Waites KB (2002) In vitro activity of ertapenem (MK-0826) against multi-drug resistant Streptococcus pneumoniae compared with 13 other antimicrobials. Int J Antimicrob Agents 20:136–140. doi:10.​1016/​S0924-8579(02)00129-2 PubMedCrossRef
8.
Zurück zum Zitat Cerquetti M, Giufrè M, Cardines R, Mastrantonio P (2007) First characterization of heterogeneous resistance to imipenem in invasive nontypeable Haemophilus influenzae isolates. Antimicrob Agents Chemother 51:3155–3161. doi:10.1128/AAC.00335-07 PubMedCrossRef Cerquetti M, Giufrè M, Cardines R, Mastrantonio P (2007) First characterization of heterogeneous resistance to imipenem in invasive nontypeable Haemophilus influenzae isolates. Antimicrob Agents Chemother 51:3155–3161. doi:10.​1128/​AAC.​00335-07 PubMedCrossRef
9.
Zurück zum Zitat Hardy DJ, Swanson RN, Rode RA, Marsh K, Shipkowitz NL, Clement JJ (1990) Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans. Antimicrob Agents Chemother 34:1407–1413PubMed Hardy DJ, Swanson RN, Rode RA, Marsh K, Shipkowitz NL, Clement JJ (1990) Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans. Antimicrob Agents Chemother 34:1407–1413PubMed
10.
Zurück zum Zitat Hoban DJ, Bouchillon SK, Johnson BM, Johnson JL, Dowzicky MJ, Tigecycline Evaluation and Surveillance Trial (TEST Program) Group (2005) In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn Microbiol Infect Dis 52:215–227. doi:10.1016/j.diagmicrobio.2005.06.001 PubMedCrossRef Hoban DJ, Bouchillon SK, Johnson BM, Johnson JL, Dowzicky MJ, Tigecycline Evaluation and Surveillance Trial (TEST Program) Group (2005) In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn Microbiol Infect Dis 52:215–227. doi:10.​1016/​j.​diagmicrobio.​2005.​06.​001 PubMedCrossRef
Metadaten
Titel
Nationwide surveillance of antimicrobial resistance among Haemophilus influenzae and Streptococcus pneumoniae in intensive care units in Taiwan
verfasst von
S.-S. Jean
P.-R. Hsueh
W.-S. Lee
H.-T. Chang
M.-Y. Chou
I.-S. Chen
J.-H. Wang
C.-F. Lin
J.-M. Shyr
W.-C. Ko
J.-J. Wu
Y.-C. Liu
W.-K. Huang
L.-J. Teng
C.-Y. Liu
Publikationsdatum
01.08.2009
Verlag
Springer-Verlag
Erschienen in
European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 8/2009
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-009-0727-3

Weitere Artikel der Ausgabe 8/2009

European Journal of Clinical Microbiology & Infectious Diseases 8/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.